Id |
Subject |
Object |
Predicate |
Lexical cue |
T264 |
0-4 |
Sentence |
denotes |
3.1. |
T265 |
6-172 |
Sentence |
denotes |
Virtual screening of prospective antiviral candidates from WS phytoconstituents on the basis of physicochemical parameters and Lipinski’s rule of five (PASS analysis) |
T266 |
173-403 |
Sentence |
denotes |
In the drug discovery context, it is generally believed that an orally active drug candidate cannot have more than one violation of Lipinski’s criteria otherwise it might compromise its bioavailability (Balakrishnan et al., 2014). |
T267 |
404-538 |
Sentence |
denotes |
Based on Lipinski's rule of five, WS phytoconstituents were previously screened and selected for their drug like properties (Table 2). |
T268 |
539-640 |
Sentence |
denotes |
As is evident from Table 2, none of the selected WS phytoconstituents exhibited Lipinski’s violation. |
T269 |
641-761 |
Sentence |
denotes |
Interestingly, standard reference drugs cinacalcet and poziotinib displayed 1 violation each of Lipinski’s rule of five. |
T270 |
762-770 |
Sentence |
denotes |
Table 2. |
T271 |
772-945 |
Sentence |
denotes |
PASS analysis of WS phytoconstituents versus FDA-approved standard reference drugs (Losartan, Procainamide, Cinacalcet, Arbidol, Hydroxychloroquine, Oberadilol, Poziotinib). |
T272 |
946-972 |
Sentence |
denotes |
Physicochemical properties |
T273 |
973-975 |
Sentence |
denotes |
S. |
T274 |
976-979 |
Sentence |
denotes |
No. |
T275 |
981-1021 |
Sentence |
denotes |
Ligands Lipinski’s rule of 5 parameters |
T276 |
1022-1243 |
Sentence |
denotes |
% Absorption(>50%)a Topological polar surface area (Å)2(TPSA)b(<160 Å) MW (<500) clog Pc(<5) Hydrogen bond donors(NOHNH)(≤5) Hydrogen bond acceptors(NON)≤10) Number of rotatable bonds(≤10) Lipinski’s violation (LV) |
T277 |
1244-1246 |
Sentence |
denotes |
1. |
T278 |
1248-1300 |
Sentence |
denotes |
Withaferin A 75.76 96.36 470.61 2.49 2 6 3 0 |
T279 |
1301-1303 |
Sentence |
denotes |
2. |
T280 |
1305-1358 |
Sentence |
denotes |
Withanolide A 75.76 96.36 470.61 2.56 2 6 2 0 |
T281 |
1359-1361 |
Sentence |
denotes |
3. |
T282 |
1363-1416 |
Sentence |
denotes |
Withanolide B 82.74 76.13 454.61 3.42 1 5 2 0 |
T283 |
1417-1419 |
Sentence |
denotes |
4. |
T284 |
1421-1474 |
Sentence |
denotes |
Withanolide D 75.76 96.36 470.61 2.56 2 6 2 0 |
T285 |
1475-1477 |
Sentence |
denotes |
5. |
T286 |
1479-1533 |
Sentence |
denotes |
Withanolide E 68.78 116.59 486.61 1.77 3 7 2 0 |
T287 |
1534-1536 |
Sentence |
denotes |
6. |
T288 |
1538-1587 |
Sentence |
denotes |
Withanone 75.76 96.36 470.61 2.60 2 6 2 0 |
T289 |
1588-1590 |
Sentence |
denotes |
7. |
T290 |
1592-1649 |
Sentence |
denotes |
Viscosalactone B 68.78 116.59 488.62 1.92 3 7 3 0 |
T291 |
1650-1652 |
Sentence |
denotes |
8. |
T292 |
1654-1703 |
Sentence |
denotes |
Anaferine 94.81 41.12 224.35 1.47 2 3 4 0 |
T293 |
1704-1706 |
Sentence |
denotes |
9. |
T294 |
1708-1761 |
Sentence |
denotes |
Withasomnine 102.85 17.83 184.24 2.65 0 2 1 0 |
T295 |
1762-1765 |
Sentence |
denotes |
10. |
T296 |
1767-1813 |
Sentence |
denotes |
Losartan 77.09 92.5 422.9 3.95 2 5 8 0 |
T297 |
1814-1817 |
Sentence |
denotes |
11. |
T298 |
1819-1870 |
Sentence |
denotes |
Procainamide 88.85 58.4 235.33 0.93 2 3 6 0 |
T299 |
1871-1874 |
Sentence |
denotes |
12. |
T300 |
1876-1923 |
Sentence |
denotes |
Cinacalcet 104.86 12 357.4 5.65 1 4 6 1 |
T301 |
1924-1927 |
Sentence |
denotes |
13. |
T302 |
1929-1971 |
Sentence |
denotes |
Arbidol 81.4 80 477.4 4.17 1 5 8 0 |
T303 |
1972-1975 |
Sentence |
denotes |
14. |
T304 |
1977-2035 |
Sentence |
denotes |
Hydroxychloroquine 92.31 48.38 335.88 3.08 2 4 9 0 |
T305 |
2036-2039 |
Sentence |
denotes |
15. |
T306 |
2041-2087 |
Sentence |
denotes |
Oberadilol 67.95 119 484 2.80 4 7 10 0 |
T307 |
2088-2091 |
Sentence |
denotes |
16. |
T308 |
2093-2141 |
Sentence |
denotes |
Poziotinib 82.57 76.6 491.3 5.29 1 7 6 1 |
T309 |
2142-2252 |
Sentence |
denotes |
Rule: aPercentage absorption was calculated as: % absorption = 109 – [0.345 × topological polar surface area]. |
T310 |
2253-2345 |
Sentence |
denotes |
bTopological polar surface area (defined as a sum of surfaces of polar atoms in a molecule). |
T311 |
2346-2419 |
Sentence |
denotes |
cLogarithm of compound partition coefficient between n-octanol and water. |
T312 |
2420-2492 |
Sentence |
denotes |
WS phytoconstituents were further analyzed using additional filters viz. |
T313 |
2493-2555 |
Sentence |
denotes |
Ghose, Veber, Egan, Muegge and Leadlikeness filters (Table 3). |
T314 |
2556-2687 |
Sentence |
denotes |
The selected phytoconstituents showed no violations of Veber, Egan and Muegge filters thereby indicating their drug-like character. |
T315 |
2688-2839 |
Sentence |
denotes |
The drug cinacalcet showed 1 and 2 violations of Egan and Muegge filters, respectively, whereas drug poziotinib exhibited 1 violation of Muegge filter. |
T316 |
2840-2848 |
Sentence |
denotes |
Table 3. |
T317 |
2850-3029 |
Sentence |
denotes |
Drug-like character of WS phytoconstituents versus FDA-approved standard reference drugs (Losartan, Procainamide, Cinacalcet, Arbidol, Hydroxychloroquine, Oberadilol, Poziotinib). |
T318 |
3030-3032 |
Sentence |
denotes |
S. |
T319 |
3033-3036 |
Sentence |
denotes |
No. |
T320 |
3038-3118 |
Sentence |
denotes |
Ligands GNo. of vio.a VNo. of vio.b ENo. of vio.c MNo. ofvio.d Leadlikeness |
T321 |
3119-3121 |
Sentence |
denotes |
1. |
T322 |
3123-3150 |
Sentence |
denotes |
Withaferin A 1 0 0 0 2 |
T323 |
3151-3153 |
Sentence |
denotes |
2. |
T324 |
3155-3183 |
Sentence |
denotes |
Withanolide A 1 0 0 0 1 |
T325 |
3184-3186 |
Sentence |
denotes |
3. |
T326 |
3188-3216 |
Sentence |
denotes |
Withanolide B 1 0 0 0 2 |
T327 |
3217-3219 |
Sentence |
denotes |
4. |
T328 |
3221-3249 |
Sentence |
denotes |
Withanolide D 1 0 0 0 1 |
T329 |
3250-3252 |
Sentence |
denotes |
5. |
T330 |
3254-3282 |
Sentence |
denotes |
Withanolide E 2 0 0 0 1 |
T331 |
3283-3285 |
Sentence |
denotes |
6. |
T332 |
3287-3311 |
Sentence |
denotes |
Withanone 1 0 0 0 1 |
T333 |
3312-3314 |
Sentence |
denotes |
7. |
T334 |
3316-3347 |
Sentence |
denotes |
Viscosalactone B 1 0 0 0 1 |
T335 |
3348-3350 |
Sentence |
denotes |
8. |
T336 |
3352-3376 |
Sentence |
denotes |
Anaferine 0 0 0 0 1 |
T337 |
3377-3379 |
Sentence |
denotes |
9. |
T338 |
3381-3408 |
Sentence |
denotes |
Withasomnine 0 0 0 0 1 |
T339 |
3409-3412 |
Sentence |
denotes |
10. |
T340 |
3414-3437 |
Sentence |
denotes |
Losartan 0 0 0 0 3 |
T341 |
3438-3441 |
Sentence |
denotes |
11. |
T342 |
3443-3470 |
Sentence |
denotes |
Procainamide 0 0 0 0 1 |
T343 |
3471-3474 |
Sentence |
denotes |
12. |
T344 |
3476-3501 |
Sentence |
denotes |
Cinacalcet 1 0 1 2 2 |
T345 |
3502-3505 |
Sentence |
denotes |
13. |
T346 |
3507-3529 |
Sentence |
denotes |
Arbidol 0 0 0 0 3 |
T347 |
3530-3533 |
Sentence |
denotes |
14. |
T348 |
3535-3568 |
Sentence |
denotes |
Hydroxychloroquine 0 0 0 0 2 |
T349 |
3569-3572 |
Sentence |
denotes |
15. |
T350 |
3574-3599 |
Sentence |
denotes |
Oberadilol 2 0 0 0 2 |
T351 |
3600-3603 |
Sentence |
denotes |
16. |
T352 |
3605-3630 |
Sentence |
denotes |
Poziotinib 2 0 0 1 2 |
T353 |
3631-3651 |
Sentence |
denotes |
Rule: aGhose filter. |
T354 |
3652-3666 |
Sentence |
denotes |
bVeber filter. |
T355 |
3667-3693 |
Sentence |
denotes |
cEgan (Pharmacial) filter. |
T356 |
3694-3717 |
Sentence |
denotes |
dMuegge (Bayer) filter. |